Personalis (PSNL) Registration Filing summary

Company overview and business model

• Develops and markets advanced cancer genomic tests and analytics for pharmaceutical research, biomarker discovery, therapy development, and clinical trial enrollment.

• Provides sequencing and data analysis services for population sequencing initiatives.

• Tests are used by physicians for cancer recurrence detection, monitoring, and therapy selection.

• Incorporated in Delaware in 2011; principal offices in Fremont, California.

Financial performance and metrics

• Raised $17,745,000 in gross proceeds from a private placement of 3,500,000 shares at $5.07 per share on August 16, 2024.

• As of August 16, 2024, 65,935,383 shares of common stock outstanding.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders.

• Bears registration and related expenses; selling stockholders bear selling commissions and related costs.